Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eisai, Biogen say lecanemab received Priority Review status in Japan » 19:12
01/29/23
01/29
19:12
01/29/23
19:12
ESALY

Eisai

$62.84 /

-1.135 (-1.77%)

, BIIB

Biogen

$290.18 /

-1.43 (-0.49%)

Eisai (ESALY) and Biogen…

Eisai (ESALY) and Biogen (BIIB) announced that an application for manufacturing and marketing approval for lecanemab, an anti-amyloid-beta protofibril antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare. Priority Review in Japan is granted to new medicines recognized as having high medical utility for serious diseases, and once designated for Priority Review, the target total review period is shortened. In Japan, Eisai submitted the manufacturing and marketing approval for lecanemab to the Pharmaceuticals and Medical Devices Agency on January 16, 2023. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.

ShowHide Related Items >><<
ESALY Eisai
$62.84 /

-1.135 (-1.77%)

BIIB Biogen
$290.18 /

-1.43 (-0.49%)

ESALY Eisai
$62.84 /

-1.135 (-1.77%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
BIIB Biogen
$290.18 /

-1.43 (-0.49%)

01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
BIIB Biogen
$290.18 /

-1.43 (-0.49%)

ESALY Eisai
$62.84 /

-1.135 (-1.77%)

BIIB Biogen
$290.18 /

-1.43 (-0.49%)

ESALY Eisai
$62.84 /

-1.135 (-1.77%)

BIIB Biogen
$290.18 /

-1.43 (-0.49%)

BIIB Biogen
$290.18 /

-1.43 (-0.49%)

Thursday
Hot Stocks
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer's disease » 18:32
01/26/23
01/26
18:32
01/26/23
18:32
BIIB

Biogen

$291.91 /

-0.61 (-0.21%)

, ESALY

Eisai

$63.97 /

-0.375 (-0.58%)

Eisai (ESALY) and Biogen…

Eisai (ESALY) and Biogen (BIIB) announced that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer's disease with confirmed amyloid pathology, for review following a standard timeline.

ShowHide Related Items >><<
ESALY Eisai
$63.97 /

-0.375 (-0.58%)

BIIB Biogen
$291.91 /

-0.61 (-0.21%)

BIIB Biogen
$291.91 /

-0.61 (-0.21%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
ESALY Eisai
$63.97 /

-0.375 (-0.58%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
BIIB Biogen
$291.91 /

-0.61 (-0.21%)

ESALY Eisai
$63.97 /

-0.375 (-0.58%)

BIIB Biogen
$291.91 /

-0.61 (-0.21%)

ESALY Eisai
$63.97 /

-0.375 (-0.58%)

BIIB Biogen
$291.91 /

-0.61 (-0.21%)

BIIB Biogen
$291.91 /

-0.61 (-0.21%)

Wednesday
Hot Stocks
Catalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII » 08:11
01/25/23
01/25
08:11
01/25/23
08:11
CPRX

Catalyst Pharmaceuticals

$16.12 /

+1.36 (+9.22%)

, ESALY

Eisai

$63.50 /

-1.99 (-3.04%)

Catalyst Pharmaceuticals…

Catalyst Pharmaceuticals (CPRX) announced that it has successfully completed the acquisition of the U.S. rights for FYCOMPA CIII, from Eisai (ESALY). The closing of the acquisition provides Catalyst with an increased U.S. commercial presence in neurology and an expanded product portfolio with an established, first-in-class, commercial stage epilepsy asset. "The completion of the acquisition of U.S. rights to FYCOMPA marks an important step in the expansion and diversification of our portfolio of marketed products, adds a second complementary commercial product that will further strengthen Catalyst's financial position through increased revenue scale, and is expected to be accretive to EBITDA and EPS in 2023," said Patrick McEnany, Chairman and CEO of Catalyst. "Coupled with the continued growth of FIRDAPSE, our flagship product, we look forward to leveraging our proven capabilities and expanded U.S. presence in neuroscience to drive organic growth for both FYCOMPA and FIRDAPSE." Strategic Rationale: The addition of FYCOMPA serves as a complementary growth driver and a strategic market adjacency within neuroscience that establishes a potential gateway for Catalyst to expand into rare epileptic diseases; Strengthens and diversifies revenues and cash flow generation with the addition of a successfully U.S. marketed asset; The acquisition of FYCOMPA is expected to be accretive to EBITDA and EPS in 2023 and provides synergies to build on the company's proven operational and commercial execution in neurology; Strategically aligns with Catalyst's growth plans to optimize the FIRDAPSE franchise and invest in portfolio expansion opportunities. Additional Transaction Details: As previously disclosed, Catalyst made a total all-cash purchase payment of $160M to Eisai. Under certain conditions, Catalyst may be obligated to pay a milestone payment and royalty. The completion of the acquisition does not impact Catalyst's previously reported 2022 full-year FIRDAPSE total net revenue guidance of $205M to $210M.

ShowHide Related Items >><<
ESALY Eisai
$63.50 /

-1.99 (-3.04%)

CPRX Catalyst Pharmaceuticals
$16.12 /

+1.36 (+9.22%)

CPRX Catalyst Pharmaceuticals
$16.12 /

+1.36 (+9.22%)

01/23/23 Piper Sandler
ANDA filing for generic Firdapse not a surprise, says Piper Sandler
01/19/23 Truist
Catalyst Pharmaceuticals price target raised to $22 from $18 at Truist
12/21/22 H.C. Wainwright
Catalyst Pharmaceuticals price target raised to $24 from $18 at H.C. Wainwright
12/19/22 Piper Sandler
Catalyst Pharmaceuticals price target raised to $20 from $18 at Piper Sandler
ESALY Eisai
$63.50 /

-1.99 (-3.04%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
CPRX Catalyst Pharmaceuticals
$16.12 /

+1.36 (+9.22%)

ESALY Eisai
$63.50 /

-1.99 (-3.04%)

ESALY Eisai
$63.50 /

-1.99 (-3.04%)

CPRX Catalyst Pharmaceuticals
$16.12 /

+1.36 (+9.22%)

Over a week ago
Hot Stocks
Ionis confirms FDA to hold advisory committee meeting on tofersen NDA » 11:53
01/23/23
01/23
11:53
01/23/23
11:53
IONS

Ionis Pharmaceuticals

$40.19 /

-0.5 (-1.23%)

, BIIB

Biogen

$289.39 /

+3.68 (+1.29%)

Ionis (IONS) issued the…

Ionis (IONS) issued the following statement about the FDA advisory committee meeting on tofersen: "On Jan. 23, the Federal Register published a notice that the U.S. Food and Drug Administration will convene a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to review data supporting the New Drug Application for tofersen, an investigational medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis - SOD1-ALS. The advisory committee meeting is scheduled for March 22, 2023. SOD1-ALS is an ultra-rare genetic form of ALS that affects approximately 330 people in the U.S.1 It is progressive, leads to the loss of everyday functions and is uniformly fatal. The NDA for tofersen has a Prescription Drug User Fee Act action date of April 25, 2023. Additional details about the advisory committee meeting can be found in a separate statement by Biogen which is available on their website." Reference Link

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$40.19 /

-0.5 (-1.23%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

IONS Ionis Pharmaceuticals
$40.19 /

-0.5 (-1.23%)

01/19/23 Piper Sandler
Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
12/21/22 Guggenheim
Ionis 2023 revenue estimate raised at Guggenheim
12/21/22 Morgan Stanley
Ionis assumed with Equal Weight from Overweight at Morgan Stanley
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
BIIB Biogen
$289.39 /

+3.68 (+1.29%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
IONS Ionis Pharmaceuticals
$40.19 /

-0.5 (-1.23%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

BIIB Biogen
$289.39 /

+3.68 (+1.29%)

Hot Stocks
Biogen says FDA to convene advisory committee meeting for tofersen » 11:17
01/23/23
01/23
11:17
01/23/23
11:17
BIIB

Biogen

$287.87 /

+2.16 (+0.76%)

Biogen announced that on…

Biogen announced that on January 23, the Federal Register published a notice that the U.S. Food and Drug Administration will convene a virtual meeting of the Peripheral and Central Nervous System Drugs Advisory Committee for the New Drug Application, or NDA, for tofersen, an investigational product for the treatment of superoxide dismutase 1, or SOD1, amyotrophic lateral sclerosis, or ALS. "The advisory committee meeting is scheduled for March 22, 2023 and will be available for live streaming. The FDA intends to make the advisory committee meeting's background materials available to the public no later than two business days before the meeting, according to the notice. The FDA said if they are unable to post the background materials on its website prior to the advisory committee meeting, the background material will be made publicly available on the FDA's website at the time of the advisory committee meeting. SOD1-ALS is an ultra-rare genetic form of ALS that affects approximately 330 people in the U.S.1, it is progressive, leads to the loss of everyday functions and is uniformly fatal. Biogen's NDA for tofersen was accepted for priority review by the FDA under the accelerated approval pathway and has a Prescription Drug User Fee Act action date of April 25, 2023," Biogen stated. Reference Link

ShowHide Related Items >><<
BIIB Biogen
$287.87 /

+2.16 (+0.76%)

BIIB Biogen
$287.87 /

+2.16 (+0.76%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
BIIB Biogen
$287.87 /

+2.16 (+0.76%)

BIIB Biogen
$287.87 /

+2.16 (+0.76%)

BIIB Biogen
$287.87 /

+2.16 (+0.76%)

BIIB Biogen
$287.87 /

+2.16 (+0.76%)

On The Fly
Fly Intel: Pre-market Movers » 09:10
01/20/23
01/20
09:10
01/20/23
09:10
NFLX

Netflix

$315.74 /

-10.78 (-3.30%)

, GOOGL

Alphabet

$93.08 /

+1.96 (+2.15%)

, GOOG

Alphabet

$93.90 /

+2.16 (+2.35%)

, JWN

Nordstrom

$17.46 /

-0.125 (-0.71%)

, CRM

Salesforce

$146.44 /

+0.98 (+0.67%)

, DOMO

Domo

$12.86 /

-0.72 (-5.30%)

, PD

PagerDuty

$26.37 /

-0.54 (-2.01%)

, LLY

Eli Lilly

$351.05 /

-0.735 (-0.21%)

, BIIB

Biogen

$280.36 /

-3.13 (-1.10%)

Check out this morning's…

ShowHide Related Items >><<
PD PagerDuty
$26.37 /

-0.54 (-2.01%)

NFLX Netflix
$315.74 /

-10.78 (-3.30%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

JWN Nordstrom
$17.46 /

-0.125 (-0.71%)

GOOGL Alphabet
$93.08 /

+1.96 (+2.15%)

DOMO Domo
$12.86 /

-0.72 (-5.30%)

CRM Salesforce
$146.44 /

+0.98 (+0.67%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

NFLX Netflix
$315.74 /

-10.78 (-3.30%)

01/20/23 Needham
Too early to buy Netflix, says Needham
01/20/23 Guggenheim
Netflix price target raised to $375 from $305 at Guggenheim
01/20/23 Canaccord
Netflix price target raised to $400 from $365 at Canaccord
01/20/23 Wells Fargo
Wells Fargo remains Overweight on Netflix following 'strong' Q4 results
GOOGL Alphabet
$93.08 /

+1.96 (+2.15%)

01/20/23 MKM Partners
MKM Partners cuts Pinterest to Neutral, sees balanced risk-reward
01/19/23 JPMorgan
JPMorgan calls out Meta as top pick ahead of earnings from online ads group
01/17/23 JMP Securities
Snap downgraded to Market Perform from Outperform at JMP Securities
01/13/23 BofA
Alphabet job cuts 'small,' but 'important signal,' says BofA
GOOG Alphabet
$93.90 /

+2.16 (+2.35%)

01/11/23 Cowen
Alphabet price target lowered to $125 from $135 at Cowen
JWN Nordstrom
$17.46 /

-0.125 (-0.71%)

01/20/23 Evercore ISI
Nordstrom price target lowered to $16 from $25 at Evercore ISI
01/20/23 Gordon Haskett
Nordstrom downgraded to Reduce from Hold at Gordon Haskett
01/20/23 JPMorgan
Nordstrom price target lowered to $13 from $15 at JPMorgan
01/05/23 Piper Sandler
Nordstrom downgraded to Neutral from Overweight at Piper Sandler
CRM Salesforce
$146.44 /

+0.98 (+0.67%)

01/20/23 Cowen
Salesforce downgraded to Market Perform at Cowen with disruption risk elevated
01/20/23 Cowen
Salesforce downgraded to Market Perform from Outperform at Cowen
01/17/23 DA Davidson
Salesforce initiated with a Neutral at DA Davidson
01/13/23 Atlantic Equities
Salesforce downgraded to Neutral from Overweight at Atlantic Equities
DOMO Domo
$12.86 /

-0.72 (-5.30%)

01/20/23 Morgan Stanley
Domo downgraded to Equal Weight from Overweight at Morgan Stanley
12/09/22 Lake Street
Domo price target lowered to $23 from $25 at Lake Street
12/09/22 Morgan Stanley
Domo price target lowered to $51 from $56 at Morgan Stanley
12/09/22 Cowen
Domo price target lowered to $23 from $27 at Cowen
PD PagerDuty
$26.37 /

-0.54 (-2.01%)

01/20/23 Morgan Stanley
PagerDuty upgraded to Overweight from Equal Weight at Morgan Stanley
12/02/22 Canaccord
PagerDuty price target lowered to $31 from $32 at Canaccord
12/02/22 Baird
PagerDuty price target lowered to $32 from $35 at Baird
10/26/22 Truist
PagerDuty price target lowered to $30 from $35 at Truist
LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

01/20/23 William Blair
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair
01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/03/23 Barclays
Eli Lilly price target raised to $400 from $395 at Barclays
12/23/22 Raymond James
ProQR Therapeutics price target raised to $5 from $2 at Raymond James
BIIB Biogen
$280.36 /

-3.13 (-1.10%)

01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
PD PagerDuty
$26.37 /

-0.54 (-2.01%)

NFLX Netflix
$315.74 /

-10.78 (-3.30%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

JWN Nordstrom
$17.46 /

-0.125 (-0.71%)

GOOGL Alphabet
$93.08 /

+1.96 (+2.15%)

DOMO Domo
$12.86 /

-0.72 (-5.30%)

CRM Salesforce
$146.44 /

+0.98 (+0.67%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

NFLX Netflix
$315.74 /

-10.78 (-3.30%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

JWN Nordstrom
$17.46 /

-0.125 (-0.71%)

GOOGL Alphabet
$93.08 /

+1.96 (+2.15%)

CRM Salesforce
$146.44 /

+0.98 (+0.67%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

PD PagerDuty
$26.37 /

-0.54 (-2.01%)

NFLX Netflix
$315.74 /

-10.78 (-3.30%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

JWN Nordstrom
$17.46 /

-0.125 (-0.71%)

GOOGL Alphabet
$93.08 /

+1.96 (+2.15%)

DOMO Domo
$12.86 /

-0.72 (-5.30%)

CRM Salesforce
$146.44 /

+0.98 (+0.67%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

NFLX Netflix
$315.74 /

-10.78 (-3.30%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

JWN Nordstrom
$17.46 /

-0.125 (-0.71%)

GOOGL Alphabet
$93.08 /

+1.96 (+2.15%)

GOOG Alphabet
$93.90 /

+2.16 (+2.35%)

CRM Salesforce
$146.44 /

+0.98 (+0.67%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

Recommendations
Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair » 08:15
01/20/23
01/20
08:15
01/20/23
08:15
BIIB

Biogen

$280.36 /

-3.13 (-1.10%)

, LLY

Eli Lilly

$351.05 /

-0.735 (-0.21%)

, ESALY

Eisai

$65.10 /

+0.49 (+0.76%)

William Blair analyst…

William Blair analyst Myles Minter noted that Eli Lilly (LLY) announced that the FDA had issued a complete response letter, or CRL, for the donanemab BLA seeking accelerated approval for the treatment of Alzheimer's disease, calling the news a "positive headline" for Eisai (ESALY) and Biogen's (BIIB) Leqembi. While he now anticipates a slight delay for donanemab to potentially enter the market in 2024, he does not believe this news has any impact on the competitive landscape until the TRAILBLAZER-ALZ2 trial reads out. Minter reiterates an Outperform rating on Biogen based on what he sees as "the substantial Leqembi opportunity."

ShowHide Related Items >><<
LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

ESALY Eisai
$65.10 /

+0.49 (+0.76%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
01/06/23 Piper Sandler
Piper stays on sidelines as commercial success of Biogen's Leqembi unsure
LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/03/23 Barclays
Eli Lilly price target raised to $400 from $395 at Barclays
12/23/22 Raymond James
ProQR Therapeutics price target raised to $5 from $2 at Raymond James
12/22/22 JMP Securities
ProQR Therapeutics shares remain 'fairly valued,' says JMP Securities
ESALY Eisai
$65.10 /

+0.49 (+0.76%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

ESALY Eisai
$65.10 /

+0.49 (+0.76%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

ESALY Eisai
$65.10 /

+0.49 (+0.76%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

LLY Eli Lilly
$351.05 /

-0.735 (-0.21%)

BIIB Biogen
$280.36 /

-3.13 (-1.10%)

Hot Stocks
Eisai submits marketing authorization application for lecanemab in Japan » 21:43
01/15/23
01/15
21:43
01/15/23
21:43
ESALY

Eisai

$63.65 /

+0.5 (+0.79%)

, BIIB

Biogen

$288.06 /

-0.02 (-0.01%)

Eisai (ESALY) and Biogen…

Eisai (ESALY) and Biogen (BIIB) announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease, or AD, and mild AD dementia with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency, or PMDA, of Japan. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

ShowHide Related Items >><<
ESALY Eisai
$63.65 /

+0.5 (+0.79%)

BIIB Biogen
$288.06 /

-0.02 (-0.01%)

ESALY Eisai
$63.65 /

+0.5 (+0.79%)

12/02/22 JonesResearch
Anavex price target raised to $80 from $40 at JonesTrading
11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
BIIB Biogen
$288.06 /

-0.02 (-0.01%)

01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
01/06/23 Piper Sandler
Piper stays on sidelines as commercial success of Biogen's Leqembi unsure
BIIB Biogen
$288.06 /

-0.02 (-0.01%)

ESALY Eisai
$63.65 /

+0.5 (+0.79%)

BIIB Biogen
$288.06 /

-0.02 (-0.01%)

ESALY Eisai
$63.65 /

+0.5 (+0.79%)

BIIB Biogen
$288.06 /

-0.02 (-0.01%)

BIIB Biogen
$288.06 /

-0.02 (-0.01%)

On The Fly
What You Missed On Wall Street This Morning » 12:16
01/11/23
01/11
12:16
01/11/23
12:16
WFC

Wells Fargo

$42.59 /

+0.24 (+0.57%)

, ALK

Alaska Air

$47.98 /

+0.73 (+1.54%)

, LUV

Southwest

$35.89 /

-0.32 (-0.88%)

, DAL

Delta Air Lines

$38.63 /

+0.54 (+1.42%)

, JBLU

JetBlue

$7.87 /

+0.175 (+2.28%)

, UAL

United Airlines

$47.28 /

+1.52 (+3.32%)

, SAVE

Spirit Airlines

$19.92 /

+0.4 (+2.05%)

, AAL

American Airlines

$15.33 /

+0.13 (+0.86%)

, FRG

Franchise Group

$30.59 /

+0.48 (+1.59%)

, CONN

Conn's

$9.95 /

+0.1 (+1.02%)

, TSLA

Tesla

$122.67 /

+3.83 (+3.22%)

, ISRG

Intuitive Surgical

$256.98 /

-14.31 (-5.27%)

, WBD

Warner Bros. Discovery

$12.67 /

+0.115 (+0.92%)

, CRM

Salesforce

$146.19 /

-1.26 (-0.85%)

, COIN

Coinbase

$42.44 /

-0.8 (-1.85%)

, KMX

CarMax

$68.11 /

+0.715 (+1.06%)

, JKS

JinkoSolar

$58.27 /

+5.04 (+9.47%)

, WWE

WWE

$88.56 /

-1.68 (-1.86%)

, STEM

Stem

$8.90 /

-0.045 (-0.50%)

, BA

Boeing

$207.58 /

+0.87 (+0.42%)

, BIIB

Biogen

$283.20 /

+1.84 (+0.65%)

, DIS

Disney

$96.07 /

+0.5 (+0.52%)

, MDRX

Veradigm

$18.22 /

+0.42 (+2.36%)

, VSCO

Victoria's Secret

$37.24 /

+2.98 (+8.70%)

, AXNX

Axonics

$62.35 /

+6.52 (+11.68%)

, TNDM

TNDM

/

+

, INMD

InMode

$33.58 /

-3.12 (-8.50%)

, LTHM

Livent

$22.92 /

+2.145 (+10.32%)

, DNA

Ginkgo Bioworks

$1.65 /

+0.11 (+7.17%)

, SABR

Sabre

$6.17 /

-0.78 (-11.23%)

, HALO

Halozyme

$50.06 /

-5.56 (-10.00%)

, GDS

GDS Holdings

$21.43 /

-2.42 (-10.15%)

Get caught up quickly on…

ShowHide Related Items >><<
WWE WWE
$88.56 /

-1.68 (-1.86%)

WFC Wells Fargo
$42.59 /

+0.24 (+0.57%)

WBD Warner Bros. Discovery
$12.67 /

+0.115 (+0.92%)

VSCO Victoria's Secret
$37.24 /

+2.98 (+8.70%)

UAL United Airlines
$47.28 /

+1.52 (+3.32%)

TSLA Tesla
$122.67 /

+3.83 (+3.22%)

TNDM TNDM
/

+

STEM Stem
$8.90 /

-0.045 (-0.50%)

SAVE Spirit Airlines
$19.92 /

+0.4 (+2.05%)

SABR Sabre
$6.17 /

-0.78 (-11.23%)

MDRX Veradigm
$18.22 /

+0.42 (+2.36%)

LUV Southwest
$35.89 /

-0.32 (-0.88%)

LTHM Livent
$22.92 /

+2.145 (+10.32%)

KMX CarMax
$68.11 /

+0.715 (+1.06%)

JKS JinkoSolar
$58.27 /

+5.04 (+9.47%)

JBLU JetBlue
$7.87 /

+0.175 (+2.28%)

ISRG Intuitive Surgical
$256.98 /

-14.31 (-5.27%)

HALO Halozyme
$50.06 /

-5.56 (-10.00%)

FRG Franchise Group
$30.59 /

+0.48 (+1.59%)

DNA Ginkgo Bioworks
$1.65 /

+0.11 (+7.17%)

DIS Disney
$96.07 /

+0.5 (+0.52%)

DAL Delta Air Lines
$38.63 /

+0.54 (+1.42%)

CRM Salesforce
$146.19 /

-1.26 (-0.85%)

CONN Conn's
$9.95 /

+0.1 (+1.02%)

COIN Coinbase
$42.44 /

-0.8 (-1.85%)

BIIB Biogen
$283.20 /

+1.84 (+0.65%)

BA Boeing
$207.58 /

+0.87 (+0.42%)

AXNX Axonics
$62.35 /

+6.52 (+11.68%)

ALK Alaska Air
$47.98 /

+0.73 (+1.54%)

AAL American Airlines
$15.33 /

+0.13 (+0.86%)

WFC Wells Fargo
$42.59 /

+0.24 (+0.57%)

01/11/23 Morgan Stanley
Wells exit from correspondent 'doesn't move EPS needle,' says Morgan Stanley
01/10/23 Odeon Capital
Wells Fargo upgraded to Buy from Hold at Odeon Capital
01/06/23 Deutsche Bank
Wells Fargo price target lowered to $50 from $60 at Deutsche Bank
01/03/23 Barclays
Wells Fargo price target raised to $64 from $58 at Barclays
ALK Alaska Air
$47.98 /

+0.73 (+1.54%)

01/11/23 Barclays
Alaska Air price target raised to $50 from $45 at Barclays
12/16/22 Goldman Sachs
Alaska Air resumed with a Buy at Goldman Sachs
12/15/22 Cowen
Copa Holdings upgraded to Outperform at Cowen amid airlines rating shake-up
12/05/22 Citi
Alaska Air initiated with a Buy at Citi
LUV Southwest
$35.89 /

-0.32 (-0.88%)

01/11/23 Jefferies
Delta Air Lines price target raised to $45 from $40 at Jefferies
01/11/23 Susquehanna
Susquehanna downgrades Southwest to Neutral on growing risks
01/11/23 Barclays
Southwest price target lowered to $42 from $48 at Barclays
01/11/23 Susquehanna
Southwest downgraded to Neutral from Positive at Susquehanna
DAL Delta Air Lines
$38.63 /

+0.54 (+1.42%)

01/11/23 Barclays
Delta Air Lines price target raised to $44 from $38 at Barclays
01/10/23 BofA
Delta Air Lines price target raised to $43 from $40 at BofA
01/05/23 Argus
Delta upgraded to Buy at Argus on strong leisure and recovery in business travel
JBLU JetBlue
$7.87 /

+0.175 (+2.28%)

12/20/22 Deutsche Bank
JetBlue price target lowered to $8.50 from $10 at Deutsche Bank
12/20/22 Deutsche Bank
Spirit Airlines downgraded on regulatory process at Deutsche Bank
12/16/22 Goldman Sachs
JetBlue resumed with a Not Rated at Goldman Sachs
12/15/22 Cowen
JetBlue downgraded to Market Perform at Cowen amid airlines rating shake-up
UAL United Airlines
$47.28 /

+1.52 (+3.32%)

01/11/23 Barclays
United Airlines price target raised to $45 from $42 at Barclays
12/16/22 Goldman Sachs
United Airlines resumed with a Buy at Goldman Sachs
SAVE Spirit Airlines
$19.92 /

+0.4 (+2.05%)

12/20/22 Deutsche Bank
Spirit Airlines downgraded to Hold from Buy at Deutsche Bank
11/01/22 Citi
Spirit Airlines price target raised to $23 from $22 at Citi
09/30/22 Citi
Spirit Airlines reinstated with a Neutral at Citi (yesterday)
AAL American Airlines
$15.33 /

+0.13 (+0.86%)

12/20/22 Deutsche Bank
American Airlines price target lowered to $20 from $25 at Deutsche Bank
12/16/22 Goldman Sachs
American Airlines resumed with a Neutral at Goldman Sachs
10/17/22 Citi
American Airlines price target lowered to $15 from $16 at Citi
FRG Franchise Group
$30.59 /

+0.48 (+1.59%)

11/04/22 Barrington
Franchise Group price target lowered to $35 from $40 at Barrington
08/05/22 B. Riley
Franchise Group price target lowered to $49 from $63 at B. Riley
07/05/22 DA Davidson
Franchise Group 'no worse off' than before without Kohl's, says DA Davidson
07/05/22 Baird
Kohl's price target lowered to $42 from $53 at Baird
CONN Conn's
$9.95 /

+0.1 (+1.02%)

12/07/22 Stephens
Conn's price target lowered to $9 from $13 at Stephens
04/11/22 Stephens
Conn's assumed with an Equal Weight at Stephens
TSLA Tesla
$122.67 /

+3.83 (+3.22%)

01/11/23 Goldman Sachs
Goldman continues to prefer Tesla and GM among automakers
01/06/23 Piper Sandler
Piper 'unsurprised' by Tesla decision to cut prices in China
01/06/23 BofA
XPeng downgraded to Neutral at BofA after Tesla price cuts
01/06/23 GLJ Research
Tesla price cuts in China 'much worse than you think,' says GLJ Research
ISRG Intuitive Surgical
$256.98 /

-14.31 (-5.27%)

01/04/23 Barclays
Intuitive Surgical price target raised to $298 from $235 at Barclays
01/03/23 BTIG
Intuitive Surgical named Top Pick for first half of 2023 at BTIG
12/22/22 Argus
Intuitive Surgical price target raised to $320 from $265 at Argus
12/12/22 Citi
Intuitive Surgical price target raised to $318 from $245 at Citi
WBD Warner Bros. Discovery
$12.67 /

+0.115 (+0.92%)

01/11/23 Guggenheim
Guggenheim upgrades Warner Bros. Discovery to Buy, sees 31% potential upside
01/11/23 Guggenheim
Warner Bros. Discovery upgraded to Buy from Neutral at Guggenheim
01/10/23 BofA
Warner Bros. Discovery added to 'US 1 List' at BofA
01/04/23 Macquarie
Warner Bros. Discovery price target lowered to $16 from $18 at Macquarie
CRM Salesforce
$146.19 /

-1.26 (-0.85%)

01/11/23 Bernstein
Salesforce downgraded to Underperform from Market Perform at Bernstein
01/09/23 Piper Sandler
Salesforce price target lowered to $171 from $175 at Piper Sandler
01/05/23 Loop Capital
Salesforce price target lowered to $140 from $150 at Loop Capital
01/05/23 Cowen
Salesforce price target lowered to $175 from $195 at Cowen
COIN Coinbase
$42.44 /

-0.8 (-1.85%)

01/11/23 DA Davidson
Coinbase price target lowered to $55 from $70 at DA Davidson
01/11/23 Mizuho
Coinbase workforce cut does not fix number one problem, says Mizuho
01/11/23 BofA
Coinbase downgraded to Underperform at BofA on below-Street 2023 view
01/11/23 BofA
Coinbase downgraded to Underperform from Neutral at BofA
KMX CarMax
$68.11 /

+0.715 (+1.06%)

01/11/23 JPMorgan
CarMax downgraded to Underweight from Neutral at JPMorgan
01/05/23 Argus
CarMax downgraded to Hold from Buy at Argus
12/28/22 Morgan Stanley
CarMax price target lowered to $75 from $90 at Morgan Stanley
12/28/22 Wedbush
Wedbush reiterates Underperform on Carvana on weakening results, liquidity
JKS JinkoSolar
$58.27 /

+5.04 (+9.47%)

01/11/23 Roth Capital
JinkoSolar upgraded to Buy from Neutral at Roth Capital
12/02/22 RBC Capital
RBC Capital 'not surprised' by Commerce Department's finding on solar companies
12/01/22 Roth Capital
U.S. to announce 'affirmative' finding in solar trade case, says Roth Capital
11/10/22 Morgan Stanley
New California 'NEM 3.0' proposal 'screens positive,' says Morgan Stanley
WWE WWE
$88.56 /

-1.68 (-1.86%)

01/10/23 Citi
Citi says WWE sale possible, ups price target to $110
01/06/23 Loop Capital
WWE price target raised to $105 from $90 at Loop Capital
01/06/23 MKM Partners
MKM Partners sees WWE as 'very attractive asset' if it goes for sale
11/29/22 Morgan Stanley
WWE price target raised to $80 from $75 at Morgan Stanley
STEM Stem
$8.90 /

-0.045 (-0.50%)

01/10/23 Morgan Stanley
Stem upgraded to Overweight from Equal Weight at Morgan Stanley
01/08/23 UBS
Stem price target lowered to $18 from $19 at UBS
10/25/22 UBS
Stem initiated with a Buy at UBS on leading position in commercial storage
10/25/22 UBS
Stem initiated with a Buy at UBS
BA Boeing
$207.58 /

+0.87 (+0.42%)

01/11/23 Wells Fargo
Boeing price target raised to $240 from $218 at Wells Fargo
01/11/23 Wells Fargo
Boeing, Equinix added to Signature Picks at Wells Fargo
01/11/23 JPMorgan
Boeing price target raised to $207 from $200 at JPMorgan
01/10/23 Morgan Stanley
Boeing downgraded to Equal Weight from Overweight at Morgan Stanley
BIIB Biogen
$283.20 /

+1.84 (+0.65%)

01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
01/06/23 Piper Sandler
Piper stays on sidelines as commercial success of Biogen's Leqembi unsure
DIS Disney
$96.07 /

+0.5 (+0.52%)

01/04/23 Macquarie
Disney price target lowered to $110 from $120 at Macquarie
12/20/22 Wells Fargo
Wells says Disney spinning ESPN/ABC 'a reasonably probable event' for late 2023
12/12/22 Morgan Stanley
Disney price target lowered to $115 from $125 at Morgan Stanley
MDRX Veradigm
$18.22 /

+0.42 (+2.36%)

12/07/22 Argus
Allscripts upgraded to Buy at Argus on expanding margins, attractive valuation
12/07/22 Argus
Allscripts upgraded to Buy from Hold at Argus
11/08/22 Goldman Sachs
Allscripts upgraded to Buy from Neutral at Goldman Sachs
11/04/22 Piper Sandler
Allscripts assumed with an Overweight at Piper Sandler
VSCO Victoria's Secret
$37.24 /

+2.98 (+8.70%)

01/05/23 UBS
UBS cuts Victoria's Secret to Sell, sees earnings outlook deteriorate in 2023
01/05/23 UBS
Victoria's Secret downgraded to Sell from Neutral at UBS
12/27/22 UBS
UBS 'not bullish' on Victoria's Secret turnaround potential
12/02/22 Cowen
Victoria's Secret price target raised to $45 from $35 at Cowen
AXNX Axonics
$62.35 /

+6.52 (+11.68%)

11/01/22 Truist
Axonics price target raised to $90 from $80 at Truist
11/01/22 Wells Fargo
Axonics price target raised to $90 from $83 at Wells Fargo
10/21/22 RBC Capital
Axonics initiated with an Outperform at RBC Capital
10/17/22 Truist
Axonics price target lowered to $80 from $85 at Truist
TNDM TNDM
/

+

12/13/22 Piper Sandler
Piper 'cautious' on Tandem Diabetes acquisition but stays Overweight
12/12/22 Citi
Tandem Diabetes price target raised to $55 from $50 at Citi
11/15/22 Wells Fargo
Wells Fargo upgrades Tandem Diabetes to Equal Weight with $43 price target
11/15/22 Wells Fargo
Tandem Diabetes upgraded to Equal Weight from Underweight at Wells Fargo
INMD InMode
$33.58 /

-3.12 (-8.50%)

12/21/22 Barclays
InMode initiated with an Overweight at Barclays
10/12/22 Jefferies
InMode initiated with a Buy at Jefferies
07/29/22 Baird
InMode price target raised to $53 from $44 at Baird
07/13/22 Baird
InMode price target lowered to $44 from $57 at Baird
LTHM Livent
$22.92 /

+2.145 (+10.32%)

01/11/23
BofA shakes up ratings to get 'more offensive' in U.S. Chemicals
01/11/23 BofA
Livent upgraded to Buy from Underperform at BofA
01/10/23 Deutsche Bank
Livent price target lowered to $22 from $30 at Deutsche Bank
01/04/23 Vertical Research
Livent upgraded to Buy from Hold at Vertical Research
DNA Ginkgo Bioworks
$1.65 /

+0.11 (+7.17%)

11/28/22 Berenberg
Berenberg starts 'well-positioned' disruptor Ginkgo Bioworks with a Buy
11/28/22 Berenberg
Ginkgo Bioworks initiated with a Buy at Berenberg
10/04/22 Morgan Stanley
Ginkgo Bioworks initiated with an Equal Weight at Morgan Stanley
08/16/22 BTIG
Ginkgo Bioworks price target raised to $6 from $5 at BTIG
SABR Sabre
$6.17 /

-0.78 (-11.23%)

01/11/23 BofA
Sabre downgraded to Underperform from Buy at BofA
10/17/22 Mizuho
Sabre price target lowered to $6 from $7 at Mizuho
09/28/22 Redburn
Sabre initiated with a Buy at Redburn
09/08/22 Mizuho
Sabre price target lowered to $7 from $8 at Mizuho
HALO Halozyme
$50.06 /

-5.56 (-10.00%)

12/21/22 Morgan Stanley
Halozyme assumed with an Overweight at Morgan Stanley
12/08/22 Benchmark
Halozyme price target raised to $68 from $55 at Benchmark
11/28/22 Wells Fargo
Halozyme initiated with an Overweight at Wells Fargo
09/09/22 Morgan Stanley
Halozyme initiated with an Overweight at Morgan Stanley
GDS GDS Holdings
$21.43 /

-2.42 (-10.15%)

11/29/22 RBC Capital
GDS Holdings price target lowered to $15 from $22 at RBC Capital
11/23/22 Truist
GDS Holdings price target lowered to $50 from $75 at Truist
11/23/22 HSBC
GDS Holdings price target lowered to $36 from $39 at HSBC
08/26/22 RBC Capital
GDS Holdings downgraded to Sector Perform from Outperform at RBC Capital
WWE WWE
$88.56 /

-1.68 (-1.86%)

WFC Wells Fargo
$42.59 /

+0.24 (+0.57%)

WBD Warner Bros. Discovery
$12.67 /

+0.115 (+0.92%)

VSCO Victoria's Secret
$37.24 /

+2.98 (+8.70%)

UAL United Airlines
$47.28 /

+1.52 (+3.32%)

TSLA Tesla
$122.67 /

+3.83 (+3.22%)

TNDM TNDM
/

+

STEM Stem
$8.90 /

-0.045 (-0.50%)

SAVE Spirit Airlines
$19.92 /

+0.4 (+2.05%)

SABR Sabre
$6.17 /

-0.78 (-11.23%)

MDRX Veradigm
$18.22 /

+0.42 (+2.36%)

LUV Southwest
$35.89 /

-0.32 (-0.88%)

LTHM Livent
$22.92 /

+2.145 (+10.32%)

KMX CarMax
$68.11 /

+0.715 (+1.06%)

JKS JinkoSolar
$58.27 /

+5.04 (+9.47%)

JBLU JetBlue
$7.87 /

+0.175 (+2.28%)

ISRG Intuitive Surgical
$256.98 /

-14.31 (-5.27%)

INMD InMode
$33.58 /

-3.12 (-8.50%)

HALO Halozyme
$50.06 /

-5.56 (-10.00%)

GDS GDS Holdings
$21.43 /

-2.42 (-10.15%)

FRG Franchise Group
$30.59 /

+0.48 (+1.59%)

DNA Ginkgo Bioworks
$1.65 /

+0.11 (+7.17%)

DIS Disney
$96.07 /

+0.5 (+0.52%)

DAL Delta Air Lines
$38.63 /

+0.54 (+1.42%)

CRM Salesforce
$146.19 /

-1.26 (-0.85%)

CONN Conn's
$9.95 /

+0.1 (+1.02%)

COIN Coinbase
$42.44 /

-0.8 (-1.85%)

BIIB Biogen
$283.20 /

+1.84 (+0.65%)

BA Boeing
$207.58 /

+0.87 (+0.42%)

AXNX Axonics
$62.35 /

+6.52 (+11.68%)

ALK Alaska Air
$47.98 /

+0.73 (+1.54%)

AAL American Airlines
$15.33 /

+0.13 (+0.86%)

  • 16
    Nov
  • 03
    Aug
WWE WWE
$88.56 /

-1.68 (-1.86%)

WFC Wells Fargo
$42.59 /

+0.24 (+0.57%)

WBD Warner Bros. Discovery
$12.67 /

+0.115 (+0.92%)

VSCO Victoria's Secret
$37.24 /

+2.98 (+8.70%)

UAL United Airlines
$47.28 /

+1.52 (+3.32%)

TSLA Tesla
$122.67 /

+3.83 (+3.22%)

STEM Stem
$8.90 /

-0.045 (-0.50%)

SAVE Spirit Airlines
$19.92 /

+0.4 (+2.05%)

SABR Sabre
$6.17 /

-0.78 (-11.23%)

LUV Southwest
$35.89 /

-0.32 (-0.88%)

JKS JinkoSolar
$58.27 /

+5.04 (+9.47%)

JBLU JetBlue
$7.87 /

+0.175 (+2.28%)

FRG Franchise Group
$30.59 /

+0.48 (+1.59%)

DIS Disney
$96.07 /

+0.5 (+0.52%)

DAL Delta Air Lines
$38.63 /

+0.54 (+1.42%)

CRM Salesforce
$146.19 /

-1.26 (-0.85%)

COIN Coinbase
$42.44 /

-0.8 (-1.85%)

BIIB Biogen
$283.20 /

+1.84 (+0.65%)

BA Boeing
$207.58 /

+0.87 (+0.42%)

ALK Alaska Air
$47.98 /

+0.73 (+1.54%)

AAL American Airlines
$15.33 /

+0.13 (+0.86%)

WWE WWE
$88.56 /

-1.68 (-1.86%)

WFC Wells Fargo
$42.59 /

+0.24 (+0.57%)

WBD Warner Bros. Discovery
$12.67 /

+0.115 (+0.92%)

VSCO Victoria's Secret
$37.24 /

+2.98 (+8.70%)

UAL United Airlines
$47.28 /

+1.52 (+3.32%)

TSLA Tesla
$122.67 /

+3.83 (+3.22%)

TNDM TNDM
/

+

STEM Stem
$8.90 /

-0.045 (-0.50%)

SAVE Spirit Airlines
$19.92 /

+0.4 (+2.05%)

SABR Sabre
$6.17 /

-0.78 (-11.23%)

MDRX Veradigm
$18.22 /

+0.42 (+2.36%)

LUV Southwest
$35.89 /

-0.32 (-0.88%)

LTHM Livent
$22.92 /

+2.145 (+10.32%)

KMX CarMax
$68.11 /

+0.715 (+1.06%)

JKS JinkoSolar
$58.27 /

+5.04 (+9.47%)

JBLU JetBlue
$7.87 /

+0.175 (+2.28%)

ISRG Intuitive Surgical
$256.98 /

-14.31 (-5.27%)

INMD InMode
$33.58 /

-3.12 (-8.50%)

HALO Halozyme
$50.06 /

-5.56 (-10.00%)

GDS GDS Holdings
$21.43 /

-2.42 (-10.15%)

DNA Ginkgo Bioworks
$1.65 /

+0.11 (+7.17%)

DIS Disney
$96.07 /

+0.5 (+0.52%)

DAL Delta Air Lines
$38.63 /

+0.54 (+1.42%)

CRM Salesforce
$146.19 /

-1.26 (-0.85%)

CONN Conn's
$9.95 /

+0.1 (+1.02%)

COIN Coinbase
$42.44 /

-0.8 (-1.85%)

BIIB Biogen
$283.20 /

+1.84 (+0.65%)

BA Boeing
$207.58 /

+0.87 (+0.42%)

AXNX Axonics
$62.35 /

+6.52 (+11.68%)

ALK Alaska Air
$47.98 /

+0.73 (+1.54%)

AAL American Airlines
$15.33 /

+0.13 (+0.86%)

WFC Wells Fargo
$42.59 /

+0.24 (+0.57%)

WBD Warner Bros. Discovery
$12.67 /

+0.115 (+0.92%)

VSCO Victoria's Secret
$37.24 /

+2.98 (+8.70%)

UAL United Airlines
$47.28 /

+1.52 (+3.32%)

TSLA Tesla
$122.67 /

+3.83 (+3.22%)

STEM Stem
$8.90 /

-0.045 (-0.50%)

SAVE Spirit Airlines
$19.92 /

+0.4 (+2.05%)

SABR Sabre
$6.17 /

-0.78 (-11.23%)

LUV Southwest
$35.89 /

-0.32 (-0.88%)

LTHM Livent
$22.92 /

+2.145 (+10.32%)

KMX CarMax
$68.11 /

+0.715 (+1.06%)

JKS JinkoSolar
$58.27 /

+5.04 (+9.47%)

JBLU JetBlue
$7.87 /

+0.175 (+2.28%)

ISRG Intuitive Surgical
$256.98 /

-14.31 (-5.27%)

INMD InMode
$33.58 /

-3.12 (-8.50%)

GDS GDS Holdings
$21.43 /

-2.42 (-10.15%)

DNA Ginkgo Bioworks
$1.65 /

+0.11 (+7.17%)

DIS Disney
$96.07 /

+0.5 (+0.52%)

DAL Delta Air Lines
$38.63 /

+0.54 (+1.42%)

CRM Salesforce
$146.19 /

-1.26 (-0.85%)

COIN Coinbase
$42.44 /

-0.8 (-1.85%)

BIIB Biogen
$283.20 /

+1.84 (+0.65%)

BA Boeing
$207.58 /

+0.87 (+0.42%)

AAL American Airlines
$15.33 /

+0.13 (+0.86%)

Periodicals
FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports » 06:27
01/11/23
01/11
06:27
01/11/23
06:27
BIIB

Biogen

$281.40 /

+6.685 (+2.43%)

U.S. Food and Drug…

U.S. Food and Drug Administration, FDA, Commissioner Robert Califf defended the FDA's decision to approve Biogen's Alzheimer's drug Aduhelm after a close cooperation between the drug's sponsor and regulators was discovered following an investigation led by House Democrats, Liz Whyte of The Wall Street Journal reports. The then-Democratic-led Oversight and Reform Committee and the Energy and Commerce Committee faulted the FDA for holding an unusual amount of meetings with Biogen as the agency weighed approving Aduhelm. The investigation found the FDA had an atypical number of meetings, calls, or substantive emails as Biogen prepared to seek approval for the drug, with 66 of those improperly documented. Reference Link

ShowHide Related Items >><<
BIIB Biogen
$281.40 /

+6.685 (+2.43%)

BIIB Biogen
$281.40 /

+6.685 (+2.43%)

01/10/23 RBC Capital
FDA review suggests high amenability for a full leca approval, says RBC Capital
01/08/23 BofA
Biogen receives 'fairly benign' label for Alzheimer's drug, says BofA
01/08/23 UBS
Biogen Alzheimer's drug label 'essentially best case,' says UBS
01/06/23 Piper Sandler
Piper stays on sidelines as commercial success of Biogen's Leqembi unsure
BIIB Biogen
$281.40 /

+6.685 (+2.43%)

BIIB Biogen
$281.40 /

+6.685 (+2.43%)

BIIB Biogen
$281.40 /

+6.685 (+2.43%)

BIIB Biogen
$281.40 /

+6.685 (+2.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.